An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment
Latest Information Update: 21 Sep 2023
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 22 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2011 New trial record